Wedbush cuts target for Denali Therapeutics stock from USD 27 to USD 23

Published on 10/27/2026 at 21:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 3, 2026. Denali Therapeutics stock costs EUR 17.28 on October 27, 2026, plus 5.85 percent versus the Frankfurt close.

Analyst target and reporting date

Wedbush cut its Denali target from USD 27.00 to USD 23.00 on October 19, 2026.
Denali is scheduled to report third-quarter 2026 results on November 3, 2026.
Denali Therapeutics stock costs EUR 17.28 at Lang & Schwarz, plus 5.85 percent versus the Frankfurt close.
The company has a USD 3.1 billion market capitalization and a USD 13.75 to USD 27.30 52-week range.

DNLI, US24823R1059, Illustration mit AI erstellt.

Denali Therapeutics (ISIN US24823R1059) faces a lower Wall Street target before its next quarterly update. On October 19, 2026, MT Newswires reported that Wedbush cut its target for Denali from USD 27.00 to USD 23.00 while keeping an Outperform rating. At Lang & Schwarz after hours on October 27, 2026 at 9:00 p.m. CET, the stock was trading at EUR 17.28, up 5.85 percent versus the Frankfurt close of October 26, 2026 at EUR 16.33.

Target cut meets a scheduled update

The Wedbush change gives the stock a fresh analyst reference ahead of Denali's next disclosed corporate date. The target reduction was 14.81 percent, calculated from USD 27.00 to USD 23.00, while the rating remained Outperform, according to the October 19 report from MT Newswires.

What does the next report bring?

GlobeNewswire carried Denali's October 22, 2026 announcement that third-quarter 2026 results, covering the period ended September 30, 2026, are scheduled for November 3, 2026 at 4:30 p.m. Eastern Time. The date provides the next defined checkpoint for the company and its pipeline update.

Revenue beat, loss missed estimates

Denali reported USD 3.60 million in second-quarter 2026 revenue, above the USD 2.15 million consensus estimate, but its USD 0.68 adjusted loss per share was wider than the USD 0.51 expected loss. MarketBeat reported those August 6, 2026 results and listed consensus expectations of USD 12.22 million revenue and a USD 0.3222 loss per share for the third quarter.

Stock stays below its yearly high

Denali's EUR 17.28 Lang & Schwarz price is 36.70 percent below the USD 27.30 52-week high and 25.67 percent above the USD 13.75 low, which are separate Nasdaq figures in the same currency as the primary listing. The latest quote gives the company a market capitalization of USD 3.1 billion, with a volume of 1,456,885 shares on October 27, 2026.

The further course of trading is shown by the continuously updated real-time quote of Denali Therapeutics stock.